FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2557697712> ?p ?o ?g. }

• W2557697712 endingPage "1578" @default.
• W2557697712 startingPage "1571" @default.
• W2557697712 abstract "Bevacizumab in combination with taxanes in HER2-negative metastatic breast cancer (MBC) patients has shown improved progression-free survival (PFS), despite the lack of clear overall survival (OS) benefit. We performed a retrospective analysis to evaluate the impact of paclitaxel-bevacizumab and of maintenance therapy with bevacizumab (BM) and endocrine therapy (ET) in the real-world practice. We identified 314 HER2-negative MBC patients treated in 12 cancer centers. Overall, the median PFS and OS were 14 and 40 months, respectively. Among the 254 patients potentially eligible for BM, 183 received BM after paclitaxel discontinuation until progression/toxicity. PFS and OS were improved in patients who had received BM in comparison with those potentially eligible but who did not receive BM (P< 0.0001 and P = 0.001, respectively). Results were confirmed when adjusting for propensity score. Among the 216 hormone-receptor positive patients eligible for BM, a more favorable PFS and OS were observed when maintenance ET was administered (P < 0.0001). Multivariate analysis showed that PS, BM, number of disease sites and maintenance ET were related to PFS, while response and maintenance ET were related to OS. In hormone-receptor positive patients, BM produced a significant PFS and a trend towards OS benefit only in absence of maintenance ET (P = 0.0007 and P = 0.06, respectively). In the triple-negative subgroup, we observed a trend towards a better OS for patients who received BM (P = 0.06), without differences in PFS (P = 0.21). Our results confirmed the efficacy of first-line paclitaxel-bevacizumab in real-world practice; both BM and maintenance ET significantly improved PFS and OS compared to no maintenance therapies. J. Cell. Physiol. 232: 1571-1578, 2017. © 2016 Wiley Periodicals, Inc." @default.
• W2557697712 created "2016-12-08" @default.
• W2557697712 creator A5002123343 @default.
• W2557697712 creator A5004436634 @default.
• W2557697712 creator A5004830992 @default.
• W2557697712 creator A5008029111 @default.
• W2557697712 creator A5010531543 @default.
• W2557697712 creator A5012371091 @default.
• W2557697712 creator A5020324515 @default.
• W2557697712 creator A5022039294 @default.
• W2557697712 creator A5024798356 @default.
• W2557697712 creator A5025243663 @default.
• W2557697712 creator A5026439843 @default.
• W2557697712 creator A5027075905 @default.
• W2557697712 creator A5034345931 @default.
• W2557697712 creator A5034632474 @default.
• W2557697712 creator A5038529742 @default.
• W2557697712 creator A5039800393 @default.
• W2557697712 creator A5039867262 @default.
• W2557697712 creator A5040744338 @default.
• W2557697712 creator A5042989547 @default.
• W2557697712 creator A5045496715 @default.
• W2557697712 creator A5051572125 @default.
• W2557697712 creator A5055332134 @default.
• W2557697712 creator A5059201916 @default.
• W2557697712 creator A5065403219 @default.
• W2557697712 creator A5067334517 @default.
• W2557697712 creator A5067681223 @default.
• W2557697712 creator A5068721926 @default.
• W2557697712 creator A5073978488 @default.
• W2557697712 creator A5080721675 @default.
• W2557697712 creator A5082366137 @default.
• W2557697712 creator A5090053504 @default.
• W2557697712 date "2016-11-30" @default.
• W2557697712 modified "2023-09-30" @default.
• W2557697712 title "A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer" @default.
• W2557697712 cites W1539571840 @default.
• W2557697712 cites W1871311056 @default.
• W2557697712 cites W1966392018 @default.
• W2557697712 cites W1967600348 @default.
• W2557697712 cites W1981065236 @default.
• W2557697712 cites W2007679672 @default.
• W2557697712 cites W2019801860 @default.
• W2557697712 cites W2021111838 @default.
• W2557697712 cites W2021416656 @default.
• W2557697712 cites W2026718377 @default.
• W2557697712 cites W2037317309 @default.
• W2557697712 cites W2047759229 @default.
• W2557697712 cites W2067198949 @default.
• W2557697712 cites W2070743887 @default.
• W2557697712 cites W2091809756 @default.
• W2557697712 cites W2099818449 @default.
• W2557697712 cites W2099824657 @default.
• W2557697712 cites W2100300361 @default.
• W2557697712 cites W2103563357 @default.
• W2557697712 cites W2118606585 @default.
• W2557697712 cites W2121690051 @default.
• W2557697712 cites W2122133396 @default.
• W2557697712 cites W2126275851 @default.
• W2557697712 cites W2126592114 @default.
• W2557697712 cites W2140088548 @default.
• W2557697712 cites W2140103603 @default.
• W2557697712 cites W2143852804 @default.
• W2557697712 cites W2160373161 @default.
• W2557697712 cites W2162352067 @default.
• W2557697712 cites W2163940216 @default.
• W2557697712 cites W2167224460 @default.
• W2557697712 cites W2172164998 @default.
• W2557697712 cites W2280392213 @default.
• W2557697712 cites W2468666928 @default.
• W2557697712 cites W2503449349 @default.
• W2557697712 cites W2600754550 @default.
• W2557697712 doi "https://doi.org/10.1002/jcp.25685" @default.
• W2557697712 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6220933" @default.
• W2557697712 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27861874" @default.
• W2557697712 hasPublicationYear "2016" @default.
• W2557697712 type Work @default.
• W2557697712 sameAs 2557697712 @default.
• W2557697712 citedByCount "16" @default.
• W2557697712 countsByYear W25576977122017 @default.
• W2557697712 countsByYear W25576977122018 @default.
• W2557697712 countsByYear W25576977122019 @default.
• W2557697712 countsByYear W25576977122020 @default.
• W2557697712 countsByYear W25576977122021 @default.
• W2557697712 countsByYear W25576977122022 @default.
• W2557697712 countsByYear W25576977122023 @default.
• W2557697712 crossrefType "journal-article" @default.
• W2557697712 hasAuthorship W2557697712A5002123343 @default.
• W2557697712 hasAuthorship W2557697712A5004436634 @default.
• W2557697712 hasAuthorship W2557697712A5004830992 @default.
• W2557697712 hasAuthorship W2557697712A5008029111 @default.
• W2557697712 hasAuthorship W2557697712A5010531543 @default.
• W2557697712 hasAuthorship W2557697712A5012371091 @default.
• W2557697712 hasAuthorship W2557697712A5020324515 @default.
• W2557697712 hasAuthorship W2557697712A5022039294 @default.
• W2557697712 hasAuthorship W2557697712A5024798356 @default.
• W2557697712 hasAuthorship W2557697712A5025243663 @default.
• W2557697712 hasAuthorship W2557697712A5026439843 @default.

• next